Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,421 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06235229 | A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma(DURGA-3) | recruiting | Phase 1 / Phase 2 | 110 | Gracell Biotechnologies (Shanghai) Co., Ltd.INDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT05530421 | Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma(SELVEDge) | recruiting | Phase 2 | 33 | University of MiamiOTHER | 1 |
| Feb 23, 2026 |
| clinicaltrials |
| NCT05974150 | Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring | recruiting | — | 25 | Carevive Systems, Inc.INDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT06100237 | Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)(REVIVE) | recruiting | Phase 2 | 50 | Carl Ola Landgren, MD, PhDOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT05745285 | Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care | recruiting | N/A | 400 | University of MiamiOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT06711705 | Elranatamab in Relapsed/Refractory Multiple Myeloma | recruiting | Phase 2 | 33 | University of California, San DiegoOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT07225738 | A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients | recruiting | — | 700 | City of Hope Medical CenterOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT05879757 | Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency | recruiting | — | 75 | TakedaINDUSTRY | 11 | Feb 18, 2026 | clinicaltrials |
| NCT07342179 | CAR-T Immunomonitoring in Multiple Myeloma (CART I5M)(CART I5M) | recruiting | N/A | 60 | Poitiers University HospitalOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT06212323 | Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial(SPOTLIGHT) | recruiting | — | 100 | University of UtahOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07403630 | INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)(IT-TCP POS) | recruiting | N/A | 300 | Azienda Ospedaliero-Universitaria di ParmaOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07413809 | Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen | recruiting | Phase 3 | 92 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07333261 | Study of BMS-986453 in Newly Diagnosed Multiple Myeloma | recruiting | Phase 1 | 25 | Susan BalOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT04645199 | National Longitudinal Cohort of Hematological Diseases(NICHE) | recruiting | — | 2,300 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06099912 | Individualized Dynamic Frailty-tailored Therapy (DynaFiT) in Elderly Patients With NDMM(DynaFiT) | recruiting | — | 131 | FengYan JinOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06015542 | Self-administration of Subcutaneous Elranatamab in the Patients' Homes.(ERICA) | recruiting | Phase 2 | 20 | Thomas LundOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT06280924 | Prehab Prior to Stem Cell Transplantation in Multiple Myeloma(MOTIVATE) | recruiting | N/A | 30 | University of AlbertaOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT05093335 | In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET | recruiting | Early Phase 1 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06574568 | A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 70 | Excyte Biopharma LtdINDUSTRY | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07390071 | Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy | recruiting | N/A | 40 | University of UtahOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT04414475 | A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. | recruiting | Phase 2 | 127 | Karyopharm Therapeutics IncINDUSTRY | 2 | Feb 2, 2026 | clinicaltrials |
| NCT07297329 | A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | recruiting | Phase 3 | 292 | Sinocelltech Ltd.INDUSTRY | 1 | Jan 29, 2026 | clinicaltrials |
| NCT04240054 | Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency(VICD) | recruiting | Phase 2 | 41 | Medical College of WisconsinOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07369895 | Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 18 | O&D BioTech Group CO., LimitedINDUSTRY | 1 | Jan 27, 2026 | clinicaltrials |
| NCT00582621 | Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders | recruiting | — | 500 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05706766 | Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation | recruiting | N/A | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT06357754 | Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy | recruiting | — | 50 | Bristol-Myers SquibbINDUSTRY | 4 | Jan 22, 2026 | clinicaltrials |
| NCT07044427 | Fall Risk Assessment and an Exercise Intervention for Prevention of Falls in Multiple Myeloma Patients(Myfall) | recruiting | N/A | 60 | University Hospital HeidelbergOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05366881 | cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease(CAMPERR) | recruiting | — | 7,000 | Adela, IncINDUSTRY | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05922501 | Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma(ISABELA) | recruiting | Phase 2 | 50 | Massachusetts General HospitalOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07336823 | JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma | recruiting | Early Phase 1 | 9 | Shenzhen Genocury Biotech Co., Ltd.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07333430 | Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 | 60 | Hadassah Medical OrganizationOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT06910124 | Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse | recruiting | Phase 2 | 32 | Dickran Kazandjian, MDOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05722405 | Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma | recruiting | Phase 4 | 100 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07093554 | Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 | 31 | Medical College of WisconsinOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT04991103 | Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE) | recruiting | Phase 2 | 40 | University of Alabama at BirminghamOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07312188 | A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 2 | 90 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07100067 | LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma | recruiting | N/A | 35 | Nanjing Legend Biotech Co.INDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT05642884 | Prehabilitation Feasibility Among Older Adults Undergoing Transplantation | recruiting | N/A | 30 | Noha Mohamed SharafeldinOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT05695508 | GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5(HD10/DSMMXX) | recruiting | Phase 2 | 160 | University of Heidelberg Medical CenterOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06247189 | ICOPE Program Feasibility in the Management of Myeloma Patients(Onco-ICOPE) | recruiting | N/A | 30 | University Hospital, ToulouseOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT07296627 | Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients(PRIMARY) | recruiting | — | 500 | Peking University People's HospitalOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT07294625 | A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma | recruiting | Early Phase 1 | 36 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT05192122 | Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD(HEME-20) | recruiting | Phase 1 | 50 | University of Illinois at ChicagoOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT04268199 | A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment(EASE) | recruiting | Phase 2 | 100 | AHS Cancer Control AlbertaOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT06518551 | Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM | recruiting | Phase 1 / Phase 2 | 49 | Omar Nadeem, MDOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT07179679 | A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors | recruiting | Phase 1 | 42 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 11, 2025 | clinicaltrials |
| NCT06251076 | Plan Development for Giving Teclistamab in the Outpatient Setting | recruiting | Phase 4 | 15 | University Health Network, TorontoOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT05556928 | Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry(CARE-Heme) | recruiting | — | 5,000 | University of Alabama at BirminghamOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT06237803 | European Myeloma Network (EMN) Sample Project(EMN36) | recruiting | — | 6,000 | European Myeloma Network B.V.NETWORK | 10 | Dec 3, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 25, 2026source: clinicaltrials